Tag Archives: NYSE MKT:TXMD

TherapeuticsMD (TXMD) Receives a Buy from Cantor Fitzgerald

In a report released today, William Tanner from Cantor Fitzgerald reiterated a Buy rating on TherapeuticsMD (NYSE MKT: TXMD), with a price target of $27. The company’s shares opened today at $5.26. Tanner said: “We reiterate the Overweight rating and

Analysts Offer Insights on Healthcare Companies: TherapeuticsMD (NYSE MKT: TXMD) and Eli Lilly & Co (NYSE: LLY)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on TherapeuticsMD (NYSE MKT:TXMD) and Eli Lilly & Co (NYSE:LLY) with bullish sentiments. TherapeuticsMD (TXMD) In a report released yesterday, William Tanner from

Oppenheimer Maintains Their Buy Rating on TherapeuticsMD (TXMD)

In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on TherapeuticsMD (NYSE MKT: TXMD), with a price target of $14. The company’s shares closed yesterday at $6.71. Olson noted: “We met management for an update on

Oppenheimer Keeps a Buy Rating on TherapeuticsMD (TXMD)

Oppenheimer analyst Jay Olson maintained a Buy rating on TherapeuticsMD (NYSE MKT: TXMD) today and set a price target of $14. The company’s shares opened today at $6.36. Olson noted: “TXMD provided a business update including initial results for the

TherapeuticsMD (TXMD) Gets a Buy Rating from Cantor Fitzgerald

Cantor Fitzgerald analyst William Tanner reiterated a Buy rating on TherapeuticsMD (NYSE MKT: TXMD) today and set a price target of $27. The company’s shares opened today at $5.25. Tanner said: “: We reiterate the Overweight rating and raise our

Cantor Fitzgerald Reaffirms Their Buy Rating on TherapeuticsMD (TXMD)

Cantor Fitzgerald analyst William Tanner maintained a Buy rating on TherapeuticsMD (NYSE MKT: TXMD) today and set a price target of $26. The company’s shares opened today at $5.19. Tanner commented: “We view TXMD as being well-positioned to launch important